A Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-3276 Injection in Patients With Advanced Malignant Tumors
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs SHR 3276 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
- 13 Jan 2025 New trial record